지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.5
- 수록면
- 125 - 132 (8page)
이용수
초록· 키워드
오류제보하기
Backgrounds/Aims: It is generally accepted that non-anatomical resection (NAR) in colorectal liver metastasis (CRLM) has comparable safety and efficacy compared to anatomical resection (AR); however, there are reports that AR may have better outcomes in KRAS mutated CRLM. This study aimed to determine the effects of KRAS mutations and surgical techniques on survival outcomes in CRLM patients.
Methods: Two hundred fifty patients who underwent hepatic resection of CRLM with known KRAS mutational status between 2007 and 2018 were analyzed. A total of 94 KRAS mutated CRLM and 156 KRAS wild-type CRLM were subdivided by surgical approach and compared for short- and long-term outcomes.
Results: In both KRAS wild-type and mutated type, there was no difference in estimated blood loss, postoperative complications, and 30-day mortality. There was no difference in disease-free survival (DFS) between AR and NAR in both groups (p = 0.326, p = 0.954, respectively). Finally, there was no difference in intrahepatic DFS between AR and NAR groups in both the KRAS groups (p = 0.165, p = 0.516, respectively).
Conclusions: The presence of KRAS mutation may not be a significant factor when deciding the approach in simultaneous resection of CRLM.
Methods: Two hundred fifty patients who underwent hepatic resection of CRLM with known KRAS mutational status between 2007 and 2018 were analyzed. A total of 94 KRAS mutated CRLM and 156 KRAS wild-type CRLM were subdivided by surgical approach and compared for short- and long-term outcomes.
Results: In both KRAS wild-type and mutated type, there was no difference in estimated blood loss, postoperative complications, and 30-day mortality. There was no difference in disease-free survival (DFS) between AR and NAR in both groups (p = 0.326, p = 0.954, respectively). Finally, there was no difference in intrahepatic DFS between AR and NAR groups in both the KRAS groups (p = 0.165, p = 0.516, respectively).
Conclusions: The presence of KRAS mutation may not be a significant factor when deciding the approach in simultaneous resection of CRLM.
목차
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Can The Presence of KRAS Mutations Guide The Type of Liver Resection during Simultaneous Resection of Colorectal Liver Metastasis?
대한외과학회 학술대회 초록집
2020 .11
-
Magnetic Resonance-Based Texture Analysis Differentiating KRAS Mutation Status in Rectal Cancer
Cancer Research and Treatment
2020 .01
-
Mutational analysis of KRAS and its clinical implications in cervical cancer patients
Journal of Gynecologic Oncology
2018 .01
-
Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Liver First Approach for Synchronous CRLM : Why and How?
대한외과학회 학술대회 초록집
2017 .11
-
Evaluation of KRAS Gene Mutations in Metastatic Colorectal Cancer Patients in Kermanshah Province
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
How successful is liver resection for colorectal cancer liver metastases in patients over 75 years old?
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .02
-
Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Living donor liver transplantation for unresectable colorectal liver metastasis: Report of a case with 13-year follow-up without recurrence
Annals of Hepato-Biliary-Pancreatic Surgery
2020 .05
-
Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
EGFR targeting antibody of GC1118 effects in Colorectal cancer with KRAS mutation
한국실험동물학회 학술발표대회 논문집
2016 .02
-
Prognostic Role of KRAS mRNA Expression in Breast Cancer
Journal of Breast Cancer
2019 .01
-
Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer
Journal of Korean Medical Science
2016 .01
-
Should vanished CRLM after chemotherapy still be resected?
한국간담췌외과학회 학술대회지
2017 .03
-
KRAS Mutation Test in Korean Patients with Colorectal Carcinomas: A Methodological Comparison between Sanger Sequencing and a Real-Time PCR-Based Assay
Journal of Pathology and Translational Medicine
2017 .01
-
p16 Hypermethylation and KRASMutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
Cancer Research and Treatment
2016 .01
-
Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer
Cancer Research and Treatment
2022 .07
-
Neoadjuvant chemotherapy might be better treatment strategy for patients with initially resectable colorectal liver metastases
대한임상종양학회 학술대회지
2021 .06
-
The prognostic impact of primary tumor site and KRAS mutation after curative intent surgery for colorectal cancer with liver metastases
대한외과학회 학술대회 초록집
2019 .10
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2022-514-001317196